Please assess the completion status of the following clinical trial:

Trial Title: Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Diagnosis of one of the following hematological malignancies:~  * CML, with 1 of the following:~    * In first CP AND failed imatinib mesylate therapy, defined as failure to obtain a hematologic remission at 3 months or a major cytogenetic response (i.e., Ph+ cells \< 35%) at 6 months or demonstrated clonal evolution or disease progression during therapy~   * In accelerated phase with \< 15% blasts~   * In blast crisis that has entered into a second CP following induction chemotherapy~ * AML, with 1 of the following:~    * In second or subsequent complete remission (CR) (i.e., \< 5% blasts by morphology, no residual leukemia by flow cytometry, and absence of cytogenetic abnormalities)~   * Failed primary induction chemotherapy, but subsequently entered into a CR with ≤ 2 subsequent re-induction chemotherapy treatment(s)~   * In first CR with intermediate-risk or poor-risk cytogenetics~ * ALL with 1 of the following:~    * In second or subsequent CR~   * In first CR AND presence of t(9;22)~ * MDS, with the following:~    * High-risk disease, defined by IPSS score of ≥ 1.5 at diagnosis AND meets 1 of the following criteria:~      * ≤ 10% blasts at diagnosis~     * In morphologic CR (\< 5% blasts) following cytoreductive chemotherapy~ * CMML, with 1 of the following:~    * ≤ 10% blasts at diagnosis~   * In morphologic CR (\< 5% blasts) following cytoreductive chemotherapy~ * CLL/PLL with the following:~    * Rai stage I-IV disease~   * Failed ≥ 1 prior chemotherapy regimen (including fludarabine phosphate) or ASCT~   * Documented chemosensitive or stable, non-bulky disease prior to transplant, defined as \< 20% bone marrow involvement AND lymph node size \< 3 cm in axial diameter~   * No bulky tumor masses, elevated lactate dehydrogenase (LDH), B symptoms, or progressive disease prior to transplant~ * Low-grade non-Hodgkin lymphoma (NHL) (i.e., small lymphocytic lymphoma, follicular center lymphoma \[grade 1 or 2\], marginal zone lymphoma, or B-cell lymphoma), with the following criteria:~    * Failed ≥ 1 prior chemotherapy regimen or ASCT~   * Documented chemosensitive or stable, non-bulky disease prior to transplant, defined as \< 20% bone marrow involvement AND lymph node size \< 3 cm in axial diameter~   * Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and involved-field radiotherapy are not considered a prior regimen)~   * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant~ * Mantle cell lymphoma, with the following:~    * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT~   * Responsive or stable disease to most recent prior therapy~   * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant~ * Intermediate-grade NHL (i.e., follicular center lymphoma \[grade 3\] or diffuse large cell lymphoma), meeting the following criteria:~    * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT~   * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites)~   * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant~ * Hodgkin lymphoma, with the following:~    * Relapsed after prior ASCT OR after ≥ 2 combination chemotherapy regimens and ineligible for ASCT~   * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites)~   * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant~ * Peripheral T-cell NHL, with the following:~    * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT~   * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites)~   * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant~* Myeloproliferative syndrome with poor risk features, meeting 1 of the following criteria:~  * \< 55 years old AND Lille score of 1~ * Lille score of 2~ * HgB \< 10 g/dL AND abnormal karyotype~* High-risk disease, with 1 of the following:~  * Age 40-72 years~ * Any age AND deemed to be at significantly increased risk of morbidity and death following a standard, myeloablative unrelated donor stem cell transplant (e.g., received extensive prior therapy, including ASCT)~* HLA-matched unrelated donor available, with 1 of the following:~  * 8/8 match at HLA-A, B, C, or DR loci by high-resolution genotyping~ * Single allelic mismatch at either the HLA-B or HLA-C loci donor by high-resolution molecular typing~    * No single allelic mismatch at HLA-A or HLA-DR loci~* KPS 80-100%~* Adapted weighted Charlson Comorbidity Index \< 3~* Serum creatinine ≤ 2.0 mg/dL~* AST or ALT \< 3 times upper limit of normal (ULN)~* Total bilirubin \< 1.5 times ULN~* LVEF ≥ 45%~* DLCO \> 50%~* No hypoxia at rest with oxygen saturation \< 92% on room air (corrected with bronchodilator therapy)~* No other severe pulmonary function abnormalities~* No HIV infection~* No active hepatitis B or C infection that, in the opinion of a gastroenterologist or the transplant committee, places the patient at moderate to high risk for developing severe hepatic disease~* No active opportunistic infection (e.g., fungal pneumonia, tuberculosis, or viral infection)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Hematopoietic Stem Cell Transplantation (Type: OTHER): All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type

Based on this trial design, predict the completion outcome and termination type (if applicable).